Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
Want to see IONS full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-1.03Last Year’s EPS
0.7Same Quarter Last Year
Strong Buy
Based on 17 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial and operational momentum—substantial year-over-year revenue growth (87%), meaningful milestone receipts (~$95M), multiple regulatory milestones and expanded product launches, plus an improved full-year revenue guide and tighter operating outlook. These positives are tempered by near-term headwinds from a price reset causing expected Q2 revenue pressure, elevated operating expenses and a large (but improving) non-GAAP operating loss, potential payer access timing delays, and an observed but described-as-managed hepatic fat signal in long-term data. On balance, the company’s growth drivers, expanded launch footprint, strengthened guidance and partner-led catalysts outweigh the challenges described.Company Guidance
Strong Quarter Revenue Growth
Total Q1 revenue of $246 million, up 87% year-over-year, driven by commercial sales and ~ $95 million in milestone/R&D revenue from partners.
Commercial Revenue Expansion
Commercial revenue increased over 42% year-over-year in Q1, supported by Tryngolza and DAWNZERA growth; Tryngolza product sales > $27 million and DAWNZERA product sales $16 million in Q1.
Improved 2026 Financial Guidance
Raised 2026 total revenue guidance to $875 million–$900 million (a $75 million increase vs prior guidance); non-GAAP operating loss now expected at $425 million–$475 million (a $75 million improvement vs prior guidance).
Cash and Balance Sheet Strength
Ended Q1 with approximately $1.9 billion in cash; repaid $633 million of 0% convertible notes and project year-end 2026 cash > $1.6 billion, supporting ongoing launches and investments.
Multiple Independent Launches and Approvals
Two independent launches underway (Tryngolza and DAWNZERA) and two additional independent launches anticipated in 2026 (olezarsen for SHTG with FDA PDUFA June 30, and zilganersen for Alexander disease with PDUFA Sept 22); Tryngolza and DAWNZERA also launching in Europe via partners (Sobi and Otsuka).
Increased Peak Sales Expectation for Olezarsen/Tryngolza
Based on HCP and payer research and priority review, annual peak sales estimate for olezarsen increased from > $2 billion to > $3 billion.
Partner Pipeline and Upcoming Catalysts
Robust partner pipeline with bepirovirsen (GSK) granted Breakthrough Therapy and priority review (PDUFA Oct 26), and two major CV outcome trials (pelacarsen HORIZON and eplontersen CARDIO-TRANSFORM) expected data this year; company expects ~5 partner-led launches by end of next year.
Commercial Execution and Go-to-Market Readiness
Full U.S. field organization deployed and trained; patient-finding initiatives yielding the strongest quarter-to-date for Tryngolza demand; company positioned to engage ~20,000 high-volume SHTG prescribers.
Product-Level 2026 Guidance Provided
For the first time, company provided product guidance: Tryngolza product sales $100 million–$110 million (full year) and DAWNZERA product sales $110 million–$120 million (full year).
Positive Clinical and Safety Narratives
CORE and CORE 2 data for olezarsen showed 72% triglyceride reduction and ~85% reduction in acute pancreatitis; long-term open-label extension data show liver fat trends returning toward baseline with no clinical sequelae reported and low discontinuation rates.
IONS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IONS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | $71.78 | $74.83 | +4.25% |
Feb 25, 2026 | $85.45 | $80.93 | -5.29% |
Oct 29, 2025 | $73.57 | $71.88 | -2.30% |
Jul 30, 2025 | $41.48 | $43.37 | +4.56% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ionis Pharmaceuticals (IONS) report earnings?
Ionis Pharmaceuticals (IONS) is schdueled to report earning on Aug 05, 2026, Before Open (Confirmed).
What is Ionis Pharmaceuticals (IONS) earnings time?
Ionis Pharmaceuticals (IONS) earnings time is at Aug 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IONS EPS forecast?
IONS EPS forecast for the fiscal quarter 2026 (Q2) is -1.03.